utideline

Utideline (UTD2) is an orally bioavailable, genetically engineered epothilone analog developed by Biostar Pharmaceuticals. As a microtubule stabilizer, it binds to the beta-subunit of tubulin, promoting tubulin polymerization and inhibiting depolymerization, which leads to cell cycle arrest and apoptosis. This mechanism is similar to that of taxanes, but utideline is designed to overcome common resistance mechanisms, such as those mediated by P-glycoprotein efflux pumps. While an injectable formulation (UTD1) is approved in China for metastatic breast cancer, UTD2 represents the oral capsule formulation currently being evaluated in clinical trials. It is primarily being developed for the first-line treatment of advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma, particularly in patients who are PD-L1-negative.

Other names

utideline capsuleutideline oral capsule